Letrozol Amarox

Letrozole, the active ingredient in Letrozol Amarox, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal hormone receptor‑positive breast cancer, helping to lower estrogen levels that can stimulate tumor growth. GNH USA supplies Letrozol Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Amarox is an aromatase inhibitor used in the management of breast cancer and related hormonal pathways. - Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth by lowering circulating estrogen. - Adjuvant treatment of early‑stage breast cancer: helps prevent disease recurrence after surgery. - Metastatic breast cancer in postmenopausal women: slows disease progression and improves survival outcomes.

Adverse reactions may occur with Letrozol Amarox and are categorized by frequency.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aches in joints or muscles. - Nausea: upset stomach, sometimes with vomiting. - Fatigue: persistent feeling of tiredness.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes, or hepatic failure. - Bone fracture: increased risk of osteoporosis‑related fractures. - Allergic reaction: rash, swelling, or difficulty breathing indicating possible anaphylaxis.

Before initiating therapy, several safety considerations are recommended. - Pregnancy contraindication: avoid use during pregnancy (Category X). - Menopause status: indicated only for postmenopausal patients. - Bone health monitoring: assess bone mineral density periodically. - Liver function: monitor hepatic enzymes before and during treatment. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letrozol Amarox may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly lower letrozole levels. - Tamoxifen: antagonistic effect on estrogen pathways, reducing therapeutic benefit. - Estrogen‑containing hormone therapy: counteracts aromatase inhibition.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential alteration of letrozole metabolism.